The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
The company is bringing precision therapies for gynaecological cancers
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Subscribe To Our Newsletter & Stay Updated
